Literature DB >> 23055857

Probable Anticonvulsant Hypersensitivity Syndrome Due to Fosphenytoin in a Pediatric Patient with Streptococcus pneumoniae Meningitis.

Nancy J Gadd1.   

Abstract

An 8-year-old previously healthy girl with Streptococcus pneumoniae meningitis developed probable anticonvulsant hypersensitivity syndrome (AHS) within 5 days of starting fosphenytoin. She experienced fever, rash, periorbital edema, profound hepatotoxicity and coagulopathy. Her sudden and dramatic rise in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) to greater than 80 times the upper limit of normal in combination with an elevated INR were very concerning. Mortality from AHS has been correlated with the degree of hepatic involvement. Fosphenytoin was immediately discontinued and, within 48 hours, AST, ALT and INR began to decrease and were within normal limits by hospital day 23. Prompt recognition of probable AHS and immediate discontinuation of fosphenytoin resulted in an abrupt reversal of clinical signs and laboratory values associated with potential hepatic failure in a pediatric patient.

Entities:  

Keywords:  adverse drug effect; anticonvulsant hypersensitivity syndrome; fosphenytoin; hepatotoxicity; pediatric

Year:  2007        PMID: 23055857      PMCID: PMC3462087          DOI: 10.5863/1551-6776-12.4.224

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  12 in total

1.  Drug-induced hypersensitivity syndrome in pediatric patients.

Authors:  M C Carroll; K A Yueng-Yue; N B Esterly; B A Drolet
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

2.  Anticonvulsant hypersensitivity syndrome.

Authors:  Sukhjot Kaur; Rashmi Sarkar; Gurvinder P Thami; Amrinder J Kanwar
Journal:  Pediatr Dermatol       Date:  2002 Mar-Apr       Impact factor: 1.588

3.  Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin.

Authors:  Jenester Mostella; Robert Pieroni; Richard Jones; Christopher K Finch
Journal:  South Med J       Date:  2004-03       Impact factor: 0.954

4.  Anticonvulsant hypersensitivity syndrome.

Authors:  A Kaminsky; M Moreno; M Díaz; V Charas; G Bravo; C Kien
Journal:  Int J Dermatol       Date:  2005-07       Impact factor: 2.736

Review 5.  Anticonvulsant hypersensitivity syndrome in children: incidence, prevention and management.

Authors:  Alberto Verrotti; Daniela Trotta; Carmela Salladini; Francesco Chiarelli
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 6.  Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.

Authors:  S R Knowles; L E Shapiro; N H Shear
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

7.  Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin.

Authors:  O Scheuerman; Y Nofech-Moses; A Rachmel; S Ashkenazi
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

8.  Antiepileptic hypersensitivity syndrome in children.

Authors:  O Bessmertny; R C Hatton; R P Gonzalez-Peralta
Journal:  Ann Pharmacother       Date:  2001-05       Impact factor: 3.154

9.  Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment.

Authors:  Sandeep B Bavdekar; Mamta N Muranjan; Nithya J Gogtay; Vishakha Kantharia; Nilima A Kshirsagar
Journal:  Ann Pharmacother       Date:  2004-08-10       Impact factor: 3.154

10.  Fosphenytoin: current place in therapy.

Authors:  Eric W Mueller; Bradley A Boucher
Journal:  J Pediatr Pharmacol Ther       Date:  2004-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.